- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00410527
Effectiveness of Short-Course Versus Standard Antibiotic Therapy in ICU Patients
Randomized, Multi-Center, Comparative Trial of Short-Course Empiric Antibiotic Therapy Versus Standard Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the Intensive Care Unit (ICU)
This study will compare two treatment strategies (standard versus short-course antibiotic therapy) for preventing resistant bacterial infection in patients in the intensive care unit (ICU). ICUs are the most frequently identified source of hospital-acquired infections. This study will examine the effectiveness of 3 days of antibiotic treatment in reducing the risk of developing antimicrobial-resistant bacteria as compared with standard antibiotic therapy of at least 8 days. It will also determine whether short-course therapy can reduce the duration and costs of ICU and hospital stays, of antibiotic treatment, and of costs involving treatment of infection-related problems.
Patients of participating institutions who are in the ICU may be eligible for this study. Candidates must be 18 years of age or older. They must have been in the hospital for at least 3 days, developed new pulmonary infiltrates (fluid or cells in the airspaces of the lungs) during their ICU stay and must be at low risk of having pneumonia.
Participants on short-course therapy take antibiotic for 3 days; those receiving standard therapy take antibiotic for at least 8 days. Both groups receive the treatment intravenously (through a vein). Sputum specimens are collected at baseline (before starting therapy) and on days 3, 10, and 28. Throat culture specimens are obtained at baseline and on days 3, 10, and 28. Nasal and anal or stool samples are collected at baseline and on days 10 and 28. Cultures of respiratory specimens obtained throughout the study period are examined for evidence of antimicrobial-resistant bacteria or the isolation of a potential pathogen. All patients are followed for 28 days after enrollment or until discharge from the hospital.
Descripción general del estudio
Descripción detallada
Tipo de estudio
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos
- University of Alabama at Birmingham
-
-
Delaware
-
Newark, Delaware, Estados Unidos, 19713
- Christiana Care Health Services
-
-
Florida
-
Miami, Florida, Estados Unidos, 33101
- University of Miami
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21224
- Johns Hopkins Bayview Medical Center
-
Baltimore, Maryland, Estados Unidos, 21201-1595
- University of Maryland, Baltimore
-
Baltimore, Maryland, Estados Unidos
- Baltimore VA
-
-
Missouri
-
Saint Louis, Missouri, Estados Unidos
- Washington University School of Medicine
-
-
Montana
-
Missoula, Montana, Estados Unidos, 59802
- St. Patrick Hospital and Health Science Center
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263
- Roswell Park Cancer Institute
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma
-
-
Texas
-
Fort Sam Houston, Texas, Estados Unidos, 78234
- Brooke Army Medical Center
-
San Antonio, Texas, Estados Unidos
- University of Texas, San Antonio
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
- INCLUSION CRITERIA:
The study will be limited to the medical, surgical, neurosurgical, trauma, and general ICUs of the participating institutions. Burn ICUs are not eligible for this study.
Subjects who meet all of the following criteria are eligible for enrollment into the study:
- Subject, or legal representative, has given written informed consent.
- Subject has developed a new pulmonary infiltrate (confirmed by radiology), after ICU admission.
- Subject has been hospitalized at least 3 days.
- CPIS less than or equal to 6.
- 18 years of age or older.
EXCLUSION CRITERIA:
Subjects who meet any of the following criteria are ineligible for participation in the study:
- Burn patients.
- Cystic fibrosis patients.
- Bone marrow or solid organ transplant patients.
- Neutropenia from any cause (absolute neutrophil count (ANC) < 500), or likely to become neutropenic within 7 days.
- Known or suspected Human Immunodeficiency Virus (HIV) infection (HIV test is not required).
- Suspected or proven extrapulmonary infection site requiring antibiotic therapy.
- History of anaphylaxis to penicillin or cephalosporins.
- History of anaphylaxis to meropenem (any component of the formulation), or other carbapenems (e.g., imipenem).
- On systemic antibiotics for more than 7 consecutive days during the previous 30 days.
- Received more than two doses of systemic antibiotics within the past 24 hours (other than those used for surgical prophylaxis).
- Pregnant or lactating. (Women of childbearing potential must have a negative serum or urine pregnancy test within the 7 days prior to the first dose of antibiotics.)
- On mechanical ventilation for > 7 consecutive days during the previous 30 days.
- Unlikely to survive past Day 7 of the study (as determined by the primary care team).
- Previous enrollment in this study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 999906231
- 06-CC-N231
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Infecciones bacterianas
-
Geisinger ClinicTerminado
-
Örebro University, SwedenTerminadoCrecimiento bacterialSuecia
-
Cornell UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); United... y otros colaboradoresTerminadoCrecimiento bacterial | Microbioma de leche humanaEstados Unidos
-
University of Santiago de CompostelaTerminadoCrecimiento bacterial | Cirugía Oral | Muelas del juicio | Cirugía del tercer molar | Gel Bioadhesivo | Bacterias de sutura | Gel Antiséptico | Chistosán | Bacterias del gel de clorhexidina | Clorhexidina-quitosano
-
Tigenix S.A.U.Cliniques universitaires Saint-Luc- Université Catholique de Louvain; Academisch... y otros colaboradoresTerminadoNeumonia bacterialEspaña, Bélgica, Francia, Italia, Lituania, Noruega
-
Merck Sharp & Dohme LLCTerminado
-
Hospital General de Niños Pedro de ElizaldeTerminado
-
Forest LaboratoriesTerminadoNeumonia bacterialEstados Unidos, Argentina, Austria, Bulgaria, Chile, Alemania, Hungría, India, Letonia, México, Perú, Polonia, Rumania, Federación Rusa, Ucrania
-
Kamuzu University of Health SciencesTerminado
Ensayos clínicos sobre Merrem
-
Joseph KutiThrasher Research FundTerminadoNeumonía | Fibrosis quística | Infección por Pseudomonas AeruginosaEstados Unidos
-
The Emmes Company, LLCThe Emmes Company, LLCTerminadoEnterocolitis necrotizante | Infección intraabdominalEstados Unidos
-
GlaxoSmithKlineTerminadoInfecciones IntestinalesEstados Unidos, Chequia, Federación Rusa, España, Canadá, Francia, Italia
-
Hoffmann-La RocheTerminadoInfecciones por bacterias gramnegativasEstados Unidos
-
PfizerTerminado
-
Tetraphase Pharmaceuticals, Inc.TerminadoApendicitis complicada | Infecciones intraabdominales complicadasUcrania, Estados Unidos, Bulgaria, Rumania, Estonia, Federación Rusa, Lituania, Hungría, Letonia, Georgia, Chequia
-
Austin HealthTerminado
-
Unity Health TorontoSunnybrook Health Sciences Centre; University of TorontoTerminadoExacerbación pulmonar de fibrosis quísticaCanadá
-
Wake Forest University Health SciencesReclutamiento
-
ShionogiTerminadoNeumonía Adquirida en el Hospital (HAP) | Neumonía asociada a la atención médica (HCAP) | Neumonía asociada al ventilador (VAP)Israel, España, Estados Unidos, Bélgica, Canadá, Chequia, Estonia, Francia, Georgia, Alemania, Hungría, Japón, Letonia, Filipinas, Puerto Rico, Federación Rusa, Serbia, Taiwán, Ucrania